| Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1) A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... Cancer discovery 7 (4), 400-409, 2017 | 773 | 2017 |
| Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal … G Cerea, M Vaghi, A Ardizzoia, S Villa, R Bucovec, S Mengo, G Gardani, ... Anticancer research 23 (2C), 1951-1954, 2003 | 137 | 2003 |
| Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1) Cancer … A Drilon, S Siena, SI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... Published by S. Karger AG, Basel www. karger. com/cro Gupta et al.: A …, 2019 | 131 | 2019 |
| First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status F Facchinetti, G Mazzaschi, F Barbieri, F Passiglia, F Mazzoni, R Berardi, ... European Journal of Cancer 130, 155-167, 2020 | 111 | 2020 |
| Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer A Amatu, A Somaschini, G Cerea, R Bosotti, E Valtorta, P Buonandi, ... British journal of cancer 113 (12), 1730-1734, 2015 | 80 | 2015 |
| Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study C Gridelli, F Morgillo, A Favaretto, F De Marinis, A Chella, G Cerea, ... Annals of oncology 22 (7), 1528-1534, 2011 | 64 | 2011 |
| Activity of EGFR TKIs in Caucasian patients with NSCLC harboring potentially sensitive uncommon EGFR mutations A Passaro, A Prelaj, L Bonanno, M Tiseo, A Tuzi, C Proto, R Chiari, ... Clinical lung cancer 20 (2), e186-e194, 2019 | 55 | 2019 |
| Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. FG De Braud, L Pilla, M Niger, S Damian, B Bardazza, A Martinetti, ... Journal of Clinical Oncology 32 (15_suppl), 2502-2502, 2014 | 50 | 2014 |
| Alka-372-001: First-in-human, phase I study of entrectinib–an oral pan-trk, ROS1, and ALK inhibitor–in patients with advanced solid tumors with relevant molecular alterations. FG De Braud, M Niger, S Damian, B Bardazza, A Martinetti, G Pelosi, ... Journal of Clinical Oncology 33 (15_suppl), 2517-2517, 2015 | 47 | 2015 |
| Treatment of metastatic neuroendocrine carcinomas based on WHO classification S Artale, L Giannetta, G Cerea, D Maggioni, P Pedrazzoli, I Schiavetto, ... Anticancer research 25 (6C), 4463-4469, 2005 | 45 | 2005 |
| Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer F Cappuzzo, A Morabito, N Normanno, P Bidoli, A Del Conte, L Giannetta, ... Lung Cancer 99, 31-37, 2016 | 35 | 2016 |
| Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non–Small-Cell Lung Cancer in Elderly Patients C Gridelli, S Novello, N Zilembo, A Luciani, AG Favaretto, F De Marinis, ... Journal of Thoracic Oncology 9 (5), 733-737, 2014 | 35 | 2014 |
| Eosinophilic myocarditis: a paraneoplastic event E Ammirati, M Stucchi, M Brambatti, F Spanò, E Bonacina, F Recalcati, ... The Lancet 385 (9986), 2546, 2015 | 32 | 2015 |
| Entrectinib for the treatment of metastatic NSCLC: safety and efficacy A Sartore-Bianchi, EG Pizzutilo, G Marrapese, F Tosi, G Cerea, S Siena Expert Review of Anticancer Therapy 20 (5), 333-341, 2020 | 31 | 2020 |
| Efficacy and safety of anti-PD-1 immunotherapy in patients aged≥ 75 years with non–small-cell lung cancer (NSCLC): an Italian, multicenter, retrospective study A Luciani, A Marra, L Toschi, D Cortinovis, S Fava, V Filipazzi, A Tuzi, ... Clinical Lung Cancer 21 (6), e567-e571, 2020 | 26 | 2020 |
| Rationale and clinical results of multi-target treatments in oncology A Sartore-Bianchi, R Ricotta, G Cerea, MR Maugeri, S Siena The International journal of biological markers 22 (1_suppl4), 77-87, 2007 | 25 | 2007 |
| Liquid biopsy for prognosis and treatment in metastatic colorectal cancer: circulating tumor cells vs circulating tumor DNA G Patelli, C Vaghi, F Tosi, G Mauri, A Amatu, D Massihnia, S Ghezzi, ... Targeted Oncology 16, 309-324, 2021 | 22 | 2021 |
| A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors AM Schram, AE Drilon, T Macarulla, EM O'Reilly, J Rodon, BM Wolpin, ... J Clin Oncol 38 (15 suppl), 2020 | 22 | 2020 |
| Cetuximab for treatment of metastatic colorectal cancer G Cerea, R Ricotta, I Schiavetto, MR Maugeri, A Sartore-Bianchi, ... Annals of Oncology 17, vii66-vii67, 2006 | 22 | 2006 |
| A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer SR Volovat, TE Ciuleanu, P Koralewski, JEG Olson, A Croitoru, K Koynov, ... Oncotarget 11 (33), 3105, 2020 | 17 | 2020 |
